Proteolysis of CCN1 by plasmin: Functional implications

Cancer Research

Volumn 65, Issue 21, 2005, Pages 9705-9711

  Pendurthi, Usha R ^a   Tran, Tien T ^a   Post, Marina ^a   Rao, L Vijaya Mohan ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE RICH PROTEIN 61; GROWTH FACTOR; PLASMIN; PROTEINASE; RECOMBINANT PROTEIN; SCLEROPROTEIN; THROMBIN;

ANGIOGENESIS; ANTIBODY SPECIFICITY; ARTICLE; BLOOD CLOTTING; BREAST CARCINOMA; CANCER CELL CULTURE; CELL ASSAY; CELL MIGRATION; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FIBRINOLYSIS; HUMAN; HUMAN CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; REGULATORY MECHANISM; UPREGULATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; ENDOTHELIAL CELLS; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PLASMIN;

EID: 27544463752     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0982     Document Type: Article

References (55)

1. Pepper MS. Role of the matrix metalloproteinases and plasminogen activator-plasmin system in angiogenesis. Arterioscler Thromb Vasc Biol 2001;21:1104-17.
2. Lijnen HR. Plasmin and matrix metalloproteinases. Thromb Haemost 2001;86:324-33.
3. Ploplis VA, Castellino FJ. Gene targeting of components of the fibrinolytic system. Thromb Haemost 2002; 87:22-31.
4. Carmeliet P, Collen D. Development and disease in proteinase-deficient mice: role of the plasminogen matrix metalloproteinase and coagulation system. Thromb Res 1998;91:255-85.
5. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor-β1 by plasmin. J Cell Biol 1990; 110:1361-7.
6. Grainger DJ, Wakefield L, Bethell HW, Farndale RW, Metcalfe JC. Release and activation of platelet latent TGF-B in blood clots during dissolution with plasmin. Nat Med 1995;1:932-7.
7. George SJ, Johnson JL, Smith MA, Jackson CL. Plasmin-mediated fibroblast growth factor-2 mobilisation supports smooth muscle cell proliferation in human saphenous vein. Vascular Res 2001;38:492-501.
8. Saksela O, Rifkin DB. Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by PA-mediated proteolytic activity. J Cell Biol 1990;110:767-75.
9. Syrovets T, Jendrach M, Rohwedder A, Schule A, Simmet T. Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKβ-mediated NF-κB activation. Blood 2001;97: 3941-50.
10. Burysek L, Syrovets T, Simmet T. The serine protease plasmin triggers expression of MCP-1 and CD40 in human primary monocytes via activation of p38 MAPK and Janus kinase (JAK)/STAT signaling pathways. J Biol Chem 2001;277:33509-17.
11. Pendurthi UR, Ngyuen M, Andrade-Gordon P, Petersen LC, Rao LVM. Plasmin induces Cyr61 gene expression in fibroblasts via protease activated receptor-1 and p44/42 mitogen-activated protein kinase-dependent signaling pathway. Arterioscler Thromb Vasc Biol 2002;22:1421-6.
12. Lau LF, Lam S. The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res 1999; 248:44-57.
13. Bork P. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 1993;327:125-30.
14. Kireeva ML, Latinkic BV, Kolesnikova TV, et al. Cyr61 and Fisp12 are both ECM-associated signaling molecules: activities, metabolism, and localization during development Exp Cell Res 1997;233:63-77.
15. 3. J Biol Chem 1998;273:3090-6.
16. Kolesnikova T, Lau LF. Human CYR61-mediated enhancement of bFGF-induced DNA synthesis in human umbilical vein endothelial cells. Oncogene 1998;16:747-54.
17. Chen C-C, Chen N, Lau LF. The angiogenic factors Cyr61 and connective tissue growth factor induce adhesive signaling in primary human skin fibroblasts. J Biol Chem 2001;276:10443-52.
18. Kireeva ML, Mo F-E, Yang GP, Lau LF. Cyr61, a product of growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol Cell Biol 1996;16:1326-34.
19. 1 and cell surface heparan sulfate proteoglycans. J Biol Chem 2000;275:24953-61.
20. 3. J Biol Chem 1999;274:24321-7.
21. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF. Cyr61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1998;95:6355-60.
22. Tsai MS, Hornby AE, Lakins J, Lupu R. Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res 2000; 60:5603-7.
23. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 2001; 61:8917-23.
24. Xie D, Yin D, Wang HJ, et al. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 2004;10:2072-81.
25. Xie D, Yin D, Tong X, et al. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and β-catenin-TCF/Lef signaling pathways. Cancer Res 2004;64:1987-96.
26. Planque N, Perbal B. A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int 2003;3:15.
27. r 10,000 forms of connective tissue growth factor. J Biol Chem 1997;272: 20275-82.
28. Perbal B, Martinerie C, Sainson R, et al. The C-terminal domain of the regulatory protein NOVH is sufficient to promote interaction with fibulin 1C: a clue for a role of NOVH in cell-adhesion signaling. Proc Natl Acad Sci U S A 1999;96:869-74.
29. Pendurthi UR, Allen KE, Ezban M, Rao LVM. Factor VIIa and thrombin induce the expression of Cyr61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa × tissue factor-induced signal transduction. J Biol Chem 2000;275: 14632-41.
30. Mandal SK, Rao LV, Tran TT, Pendurthi UR. A novel mechanism of plasmin-induced mitogenesis in fibroblasts. J Thromb Haemost 2005;3:163-9.
31. Ploplis VA, Castellino FJ. Nonfibrinolytic functions of plasminogen. Methods 2000;21:103-10.
32. Reuning U, Magdolen V, Wilhelm O, et al. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int J Oncol 1998;13:893-906.
33. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25-40.
34. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993;73: 161-95.
35. Chapman HA, Wei Y. Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb Haemost 2001;86:124-9.
36. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost 2001;86:346-55.
37. Perbal B. CCN proteins: multifunctional signalling regulators. Lancet 2004;363:62-4.
38. Brigstock DR. The CCN family: a new stimulus package. J Endocrinol 2003;178:169-75.
39. O'Brien TP, Yang GP, Sanders L, Lau LF. Expression of cyr61, a growth factor-inducible immediate-early gene. Mol Cell Biol 1990;10:3569-77.
40. Schutze N, Lechner A, Groll C, et al. The human analog of murine cysteine rich protein 61 is a 1α,25-dihydroxyvitamin D3 responsive immediate early gene in human fetal osteoblasts: regulation by cytokines, growth factor and serum. Endocrinology 1998;139: 1761-70.
41. Kunz M, Moeller S, Koczan D, et al. Mechanisms of hypoxic gene regulation of angiogenesis factor Cyr61 in melanoma cells. J Biol Chem 2003;278: 45651-60.
42. 3, independent of its carboxyl-terminal domain. J Biol Chem 2001;276:21943-50.
43. 1 in human umbilical vein endothelial cells. J Biol Chem 2002;277:46248-55.
44. 3 binding site in CCN1 (CYR61) critical for pro-angiogenic activities in vascular endothelial cells. J Biol Chem 2004;279: 44166-76.
45. Xie D, Miller CW, O'Kelly J, et al. Breast cancer. Cyr61 is overexpressed, estrogen-inducible and associated with more advanced diseases. J Biol Chem 2001;276: 14187-94.
46. Tsai MS, Bogart DF, Li P, Mehmi I, Lupu H. Expression and regulation of Cyr61 in human breast cancer cell lines. Oncogene 2002;21:964-73.
47. Chappuis PO, Dieterich B, Sciretta V, et al. Functional evaluation of plasmin formation in primary breast cancer. J Clin Oncol 2001;19:2731-8.
48. Brown LF, Dvorak AM, Dvorak HF. Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. Am Rev Respir Dis 1989;140:1104-7.
49. Schwarz DA, Barry G, Mackay KB, et al. Identification of differentially expressed genes induced by transient ischemic stroke. Brain Res Mol Brain Res 2002; 101:12-22.
50. 2 as an adhesion receptor on peripheral blood monocytes for Cyr61 (CCN1) and connective tissue growth factor (CCN2): immediate-early gene products expressed in atherosclerotic lesions. Blood 2002;99:4457-65.
51. Hilfiker A, Hilfiker-Kleiner D, Fuchs M, et al. Expression of CYR61, an angiogenic immediate early gene, in arteriosclerosis and its regulation by angiotensin II. Circulation 2002;106:254-60.
52. Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 1999;56:104-32.
53. Li W-Y, Chong SSN, Huang EY, Tuan T-L. Plasminogen activator/plasmin system: a major player in wound healing. Wound Repair Regen 2003;11:239-47.
54. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991;88:1067-72.
55. Riser BL, Cortes P, DeNichilo M, et al. Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report. Kidney Int 2003;64:451-8.